18F-FES PET/CT对复发或转移性乳腺癌管理临床决策的影响
本研究从2021至2023年前瞻性试验的上市后监测数据库中回顾性识别344例疑似或已知复发或转移性雌激素受体阳性乳腺癌患者,评估18F-FES PET/CT前后管理计划的变化。120例(35%)在18F-FES PET/CT后管理发生改变,139例(40%)支持原有决策而未改变;病灶18F-FES阴性者改变率44%(36/81),高于阳性者30%(51/172)和混合者36%(33/91)。
要点
- 344例中120例(35%)在18F-FES PET/CT后管理发生改变,139例(40%)支持原有决策。
- 所有改变中,意向治疗改变占64%(77/120),跨学科改变占68%(82/120)。
- 18F-FES阴性病灶改变率44%(36/81),高于阳性30%(51/172)和混合36%(33/91)。
核心结论
- 18F-FES PET/CT改变了复发或转移性乳腺癌的管理,在临床实践中是有影响力的影像学方法。
研究设计与样本
- 从2021至2023年前瞻性试验的上市后监测数据库中回顾性识别研究对象。
- 纳入基于常规标准检查疑似或已知复发或转移性雌激素受体阳性乳腺癌的患者。
- 由2名经验丰富的肿瘤内科医生通过病历回顾评估18F-FES PET/CT前计划管理和后实际管理。
- 提供5点问卷评估18F-FES PET/CT对管理计划的价值。
- 分析意向治疗和跨学科改变率,以及根据PET/CT结果或临床指征的18F-FES PET/CT影响。
主要发现
- 344例纳入患者中,120例(35%)在18F-FES PET/CT后管理发生改变。
- 139例(40%)患者中,18F-FES PET/CT支持现有管理决策而无管理改变。
- 意向治疗改变和跨学科改变分别占所有改变的64%(77/120)和68%(82/120)。
- 病灶18F-FES阴性时改变率44%(36/81),高于18F-FES阳性30%(51/172)或混合18F-FES阳性/阴性36%(33/91)。
- 临床指征方面,评估双原发癌转移来源时改变率最高,为64%(9/14)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical impact of 16α-18F-fluoro-17β-estradiol (18F-FES) PET/CT on patient management has not been well investigated. The aim of this study was to assess the clinical impact of 18F-FES PET/CT on the management of patients with recurrent or metastatic breast cancer. Methods: Study subjects were identified retrospectively from a database of a prospective trial for postmarketing surveillance of 18F-FES between 2021 and 2023. Patients who were suspected or known to have recurrent or metastatic estrogen receptor-positive breast cancer based on a routine standard workup were included. Planned management before and actual management after 18F-FES PET/CT were assessed by 2 experienced medical oncologists via medical chart review. A 5-point questionnaire was provided to evaluate the value of 18F-FES PET/CT for management planning. The rate of intention-to-treat and interdisciplinary changes, and the impact of 18F-FES PET/CT according to PET/CT result or clinical indication, were examined. Results: Of the 344 included patients, 120 (35%) experienced a change in management after 18F-FES PET/CT. In 139 (40%) patients,18F-FES PET/CT supported the existing management decision without a change in management. Intention-to-treat and interdisciplinary changes accounted for 64% (77/120) and 68% (82/120) of all changes, respectively. A higher rate of change was observed when lesions were 18F-FES-negative (44% [36/81]) than 18F-FES-positive (30% [51/172]) or mixed 18F-FES-positive/negative (36% [33/91]). Regarding clinical indications, the highest rate of change was shown when evaluating the origins of metastasis of double primary cancers (64% [9/14]). Conclusion: 18F-FES PET/CT modified the management of recurrent or metastatic breast cancer, serving as an impactful imaging modality in clinical practice.
引用
- Ryu J, Hyung J, Han S, et al. Impact of 18F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer. J Nucl Med. 2024. PMID: 39362758. doi:10.2967/jnumed.124.267913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。